Seelos Therapeutics, Inc. (SEELQ)
$0.00
$0.00 (0.00%)As on 10-Sep-2026 16:00EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Seelos Therapeutics, Inc (SEELQ)
| -- | 0.0 | 0.0 | -- | -99.7 | -97.4 | -89.0 |
|
BSE Sensex*
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Seelos Therapeutics, Inc (SEELQ)
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an... intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Read more
-
CEO, Founder, President & Chairman
Dr. Raj Mehra J.D., Ph.D.
-
Chief Financial Officer
Mr. Michael J. Golembiewski
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Seelos Therapeutics, Inc (SEELQ)
What is the current share price of Seelos Therapeutics, Inc (SEELQ) Today?
The share price of Seelos Therapeutics, Inc (SEELQ) is $0.00 (NASDAQ) as of 10-Sep-2026 16:00 EDT. Seelos Therapeutics, Inc (SEELQ) has given a return of -99.71% in the last 3 years.
What is the current PB & PE ratio of Seelos Therapeutics, Inc (SEELQ)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
0.00 |
0.00 |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2023 |
0.00 |
0.00 |
What is the 52 Week High and Low of Seelos Therapeutics, Inc (SEELQ)?
The 52-week high and low of Seelos Therapeutics, Inc (SEELQ) are Rs 0.01 and Rs 0.00 as of 12-Sep-2026.
What is the market cap of Seelos Therapeutics, Inc (SEELQ)?
Seelos Therapeutics, Inc (SEELQ) has a market capitalisation of $ 0 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Seelos Therapeutics, Inc (SEELQ)?
Before investing in Seelos Therapeutics, Inc (SEELQ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.